Dr. Reddy's Laboratories Ltd (RDY) by event type
RDY moves most on analyst downgrades — a median of +0.18% at 30 minutes across 18 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the RDY overview →
How RDY reacts across 2 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 1,296 of 2,717 | 16 | +0.03% | 63% | -0.14% |
| Analyst downgrades 816 of 2,603 | 18 | +0.18% | 67% | +0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how RDY usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · RDY overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OBALON THERAPEUTICS (OBLN) | 532 | -0.09% | 42% |
| Oncolytics Biotech Inc. - Common Shares (ONCY) | 530 | -0.06% | 43% |
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Quest Diagnostics Incorporated (DGX) | 524 | +0.03% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.